Immunogenicity and safety of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine (PRV) in Indian infants

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 1, 2013, Pages 172-176

  Lokeshwar, M R ^a   Bhave, Sheila ^b   Gupta, Ashok ^c   Goyal, V K ^d   Walia, Anuj ^e  

^a Department of Paediatrics   (India)

^b KEM HOSPITAL   (India)

^c SMS Hospital   (India)

^d Panchsheel Hospitals Pvt Ltd Delhi   (India)

^e MSD Pharmaceuticals Pvt Ltd   (India)

Author keywords

Immunogenicity; Oral pentavalent rotavirus vaccine; Seroconversion; Serum anti rotavirus IgA antibodies; Vaccine report cards

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; NEUTRALIZING ANTIBODY; ROTAVIRUS VACCINE;

AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; IMMUNOGENICITY; INDIAN; INFANT; MAJOR CLINICAL STUDY; MENINGITIS; MULTICENTER STUDY; NONHUMAN; OUTCOME ASSESSMENT; OUTPATIENT CARE; ROTAVIRUS INFECTION; SEROCONVERSION; SINGLE BLIND PROCEDURE; VOMITING;

ANTIBODIES, VIRAL; DRUG TOXICITY; FEMALE; HUMANS; IMMUNOGLOBULIN A; INDIA; INFANT; MALE; ROTAVIRUS VACCINES; VACCINATION;

EID: 84874743783     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22341     Document Type: Article

References (17)

1. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006; 12:304-6; PMID:16494759; http://dx.doi.org/10.3201/eid1202.050006.
2. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics 2007; 119:171-82; PMID:17200286; http://dx.doi.org/10.1542/peds.2006- 3134.
3. Parashar UD, Alexander JP, Glass RI; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-12):1-13; PMID:16902398.
4. Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200(Suppl 1):S9-15; PMID:19817620; http://dx.doi.org/10.1086/ 605025.
5. Steele AD, Patel M, Parashar UD, Victor JC, Aguado T, Neuzil KM. Rotavirus vaccines for infants in developing countries in Africa and Asia: considerations from a world health organization-sponsored consultation. J Infect Dis 2009; 200(Suppl 1):S63-9; PMID:19817616; http://dx.doi.org/10.1086/605042.
6. Tate JE, Chitambar S, Esposito DH, Sarkar R, Gladstone B, Ramani S, et al. Disease and economic burden of rotavirus diarrhoea in India. Vaccine 2009; 27(Suppl 5):F18-24; PMID:19931713; http://dx.doi.org/10.1016/j.vaccine.2009.08. 098.
7. Kang G, Arora R, Chitambar SD, Deshpande J, Gupte MD, Kulkarni M, et al.; Indian Rotavirus Strain Surveillance Network. Multicenter, hospital-based surveillance of rotavirus disease and strains among indian children aged <5 years. J Infect Dis 2009; 200(Suppl 1):S147-53; PMID:19817593; http://dx.doi.org/10.1086/605031.
8. Rotavirus vaccines:an update. [English, French.]. Wkly Epidemiol Rec 2009; 84:533-40; PMID:20034143.
9. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010; 201:1617-24; PMID:20402596; http://dx.doi.org/10. 1086/652403.
10. Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243-51; PMID:19491186; http://dx.doi.org/10.1001/jama.2009.756.
11. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al.; Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33; PMID:16394299; http://dx.doi.org/10.1056/ NEJMoa052664.
12. Ciarlet M, Schödel F. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq. Vaccine 2009; 27(Suppl 6):G72-81; PMID:20006144; http://dx.doi.org/10. 1016/j.vaccine.2009.09.107.
13. Ciarlet M, Sani-Grosso R, Yuan G, et al. Safety and immunogenicity of concomitant use of the pentavalent rotavirus vaccine (RotaTeqTM) and oral poliovirus vaccine (OPV). Presented at: European Society for Pediatric Infectious Diseases (ESPID). Porto, Portugal, 2-4 May 2007.
14. Narang A, Bose A, Pandit AN, Dutta P, Kang G, Bhattacharya SK, et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Hum Vaccin 2009; 5:414-9; PMID:19276664.
15. Centers for Disease Control and Prevention (CDC). Reduction in rotavirus after vaccine introduction-United States, 2000-2009. MMWR Morb Mortal Wkly Rep 2009; 58:1146-9; PMID:19847149.
16. Link: http://www.iapcoi.com/pdf/13-%20ROTA%20 VIRUS%20VACCINES.pdf as accessed on 6 July 2011.
17. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, doubleblind, placebo-controlled trial. Lancet 2010; 376:615-23; PMID:20692031; http://dx.doi.org/10.1016/S0140-6736(10)60755-6.